Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Standard BioTools ( (LAB) ) has provided an announcement.
On September 13, 2025, Standard BioTools Inc. initiated a restructuring plan, which includes a 15% reduction in its global workforce. This move aims to enhance operational efficiency and align costs with revenue projections, supporting the company’s long-term strategic goals. The restructuring is expected to incur expenses of approximately $7.5 million, primarily for severance and termination benefits, with potential for additional unforeseen costs.
The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance, characterized by declining revenues and negative profit margins. Technical analysis provides some neutral support, but poor valuation metrics further weigh down the score.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc. operates in the biotechnology industry, focusing on providing innovative tools and solutions to enhance biological research and development.
Average Trading Volume: 1,818,678
Technical Sentiment Signal: Sell
Current Market Cap: $523.3M
Find detailed analytics on LAB stock on TipRanks’ Stock Analysis page.